EverHint Lens - Novavax, Inc. (NVAX) - Stock Analysis - February 27, 2026

Analysis Date: 2026-02-27
Sector: Healthcare
Industry: Biotechnology
Exchange: N/A

Executive Summary

Novavax, Inc. is currently trading at $11.19 (🟢 +17.42% today) with a market capitalization of $1.82B.

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate.

Price & Valuation

Close Price: $11.19
Volume: 23.8M
Day Range: $9.70 - $11.97
52-Week Range: $5.01 - $11.97
P/E Ratio: N/A

After-Hours Trading:

• Bid: $10.97
• Ask: $11.12
• Volume: 23,919,407.15516
• Last Update: 7:55 PM ET

DCF Valuation: Not applicable (negative intrinsic value)
DCF model (unlevered) calculated as of 2026-02-26.

Market Context

Healthcare Sector: -0.81777% | Sector P/E: 34.11

Major Indices:

• S&P 500: $6908.86 (🔴 -0.54%)
• NASDAQ Composite: $22878.38 (🔴 -1.18%)
• Dow Jones Industrial Average: $49499.20 (🟢 +0.03%)

Peer Comparison

Peer comparison (11 companies):

• NVAX - Novavax, Inc. ($11.19, +17.4%, $1.82B) ← Current
• TERN - Terns Pharmaceuticals, Inc. ($40.92, -1.1%, $3.69B)
• WVE - Wave Life Sciences Ltd. ($15.36, +5.6%, $2.81B)
• NTLA - Intellia Therapeutics, Inc. ($14.28, +6.4%, $1.65B)
• TRVI - Trevi Therapeutics, Inc. ($11.52, +1.4%, $1.48B)
• NKTR - Nektar Therapeutics ($65.90, -6.4%, $1.34B)
• ORIC - ORIC Pharmaceuticals, Inc. ($13.50, +0.7%, $1.31B)
• PGEN - Precigen, Inc. ($3.81, -0.8%, $1.14B)
• ZBIO - Zenas BioPharma, Inc. ($26.36, +1.3%, $1.10B)
• CVAC - CureVac N.V. ($4.66, 0.0%, $1.05B)
• UPB - Upstream Bio, Inc. ($7.90, +2.1%, $427M)

Financial Performance

Latest Quarter (2025-12-31):

• Revenue: $147.14M
• Net Income: $17.53M
• EPS: $0.09
• Revenue Growth (QoQ): +108.9%

Stock Split History

NVAX has executed 1 stock split(s) historically

• 2019-05-10: 1-for-20 split

Cumulative Split Factor: 0x (1 share in 1987 = 0 shares today)

Most recent split: 1-for-20 on 2019-05-10

Earnings Calendar

Next Earnings Report: 2026-05-14 (Before Market Open)

• EPS Estimate: $-0.35
• Revenue Estimate: $0.08B

Most Recent Report: 2026-02-26

• EPS: $0.10 (Est: $-0.66) ✓ Beat
• Revenue: $0.15B

Historical Data: 121 earnings events tracked

Analyst Outlook

Analyst Price Target Consensus:

• Target: $14.50 (+29.6% upside)
• Range: $11.00 - $18.00
• Median: $14.50

Next Quarter Estimates (2026-12-30):

• Revenue: $111.72M
• EPS: $0.16

Analyst Consensus

Overall Rating: Buy

Rating Distribution (225 total ratings):

• 🟢 Buy/Outperform: 163 (72.4%)
• ⚪ Hold/Neutral: 43 (19.1%)
• 🔴 Sell/Underperform: 19 (8.4%)

Recent Analyst Actions:

• BTIG (2026-01-20): Maintained Buy
• JP Morgan (2025-11-18): Maintained Underweight
• B. Riley Securities (2025-11-10): Maintained Buy
• TD Cowen (2025-11-04): Maintained Hold
• HC Wainwright & Co. (2025-10-23): Maintained Buy

Consensus based on 225 analyst ratings from major financial institutions

Trading Signals

Our technical analysis identified 2 trading signal(s) in the last 60 days:

• 2026-02-26: Momentum Swing - breakout @ $11.19
• 2026-01-13: Sma20 Sma50 - SMA20_x_SMA50_Buy @ $8.67

Insider Activity

Recent Transactions (Last 10):

• Buys: 4
• Sells: 6

Notable Transactions:

• 2026-01-23: Jacobs John C - Buy (Option Exercise, 83,197 shares)
• 2026-01-23: Jacobs John C - Sell (Tax Withholding, 39,132 shares @ $9.17)
• 2026-01-23: Jacobs John C - Sell (Option Exercise, 83,197 shares)

Congressional Trading Activity

Tracking recent stock transactions by U.S. Congress members

U.S. Senate: 2 transactions tracked

Recent Activity:

• ⚪ Pat Roberts: Sale (Full) (Spouse) on 2020-10-13, Amount: $1,001 - $15,000
• 🟢 Pat Roberts: Purchase (Spouse) on 2020-08-17, Amount: $1,001 - $15,000

Congressional trading data sourced from official disclosure filings

News Sentiment Analysis

AI Analysis (based on 30 recent articles):

Recent news for Novavax (NVAX) is predominantly positive, driven by Q4 2025 earnings beats, a swing to profit, and raised 2026 revenue outlook amid vaccine deals. Strategic partnerships, including the Pfizer licensing agreement worth up to $500M, and Zacks upgrade to Buy further bolster optimism. While some stock dips and institutional selling occurred, investor attention remains high.

Key Themes:

• Earnings Beat and Profitability
• Strategic Partnerships and Licensing
• Investor Conferences and Upgrades

Sentiment: Positive (92% confidence)

Reddit Sentiment

Community Discussion (last 30 days from r/wallstreetbets, r/stocks, r/investing):

Overall Sentiment: Bullish 📈 (Score: 0.936)

Post Analysis:

• Total posts: 1
• Bullish: 1 (100.0%)
• Bearish: 0 (0.0%)
• Neutral: 0 (0.0%)
• Total engagement: 62 (upvotes + comments)

Note: Sentiment score ranges from -1.0 (very bearish) to +1.0 (very bullish), weighted by post engagement.

Recent News

5 most recent articles covering NVAX:

• Novavax to Participate in Upcoming Investor Conferences (PRNewsWire, 2026-02-26) — Read more
• Novavax, Inc. (NVAX) Q4 2025 Earnings Call Transcript (Seeking Alpha, 2026-02-26) — Read more
• COVID-19 Vaccine Maker Novavax Swings To Profit As Sales Climb (Benzinga, 2026-02-26) — Read more
• Novavax (NVAX) Beats Q4 Earnings and Revenue Estimates (Zacks Investment Research, 2026-02-26) — Read more
• S&P 500, Nasdaq Struggle Amid AI Rotation Pain (Schaeffers Research, 2026-02-26) — Read more

Full news analysis based on 30 recent articles

Generated by Everhint Lens - Quantitative Stock Analysis
Last updated: 2026-02-26 10:54:15 PM PST

Disclaimer: This is not investment advice. Always do your own research before making investment decisions.